Shares of PTC Therapeutics Inc. (NASDAQ:PTCT) surged Friday after the company’s drug Translarna moved closer to approval in the European Union. A panel that advises the EU’s drug and medical device agency said it believes Translarna should get conditional marketing approval. The drug is designed to treat a type of Duchenne muscular dystrophy, a rare and fatal genetic disease. PTC Therapeutics, Inc. (NASDAQ:PTCT) weekly performance is 32.91%. On last trading day company shares ended up $20.03. Analysts mean target price for the company is $38.33. PTC Therapeutics, Inc. (NASDAQ:PTCT) distance from 50-day simple moving average (SMA50) is -7.44%.
Novavax, Inc. (NASDAQ:NVAX) on May 12 announced follow-up data from its dose-ranging Phase 1 clinical trial of its respiratory syncytial virus (RSV) F-protein vaccine in 220 elderly adults (60 years of age and older, with a mean age of 68) that was initiated in October 2012. In the placebo-controlled trial, subjects received a single injection of either 60ug or 90ug of the RSV F-protein vaccine candidate, with or without aluminum phosphate as an adjuvant. Novavax, Inc. (NASDAQ:NVAX) shares advanced 7.06% in last trading session and ended the day on $4.85. NVAX gross Margin is 61.20% and its return on assets is -28.20%.Novavax, Inc. (NASDAQ:NVAX) quarterly performance is -19.30%.
Prosensa Holding (NYSE:RNA) announced its earnings results on 20 May. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.25, Analyst Ratings News reports. Prosensa Holding NV (NASDAQ:RNA) shares moved up 27.04% in last trading session and was closed at $8.41, while trading in range of $7.65 – $8.96. Prosensa Holding NV (NASDAQ:RNA) year to date (YTD) performance is 80.09%.
On May 19, 2014, Array BioPharma Inc. (NASDAQ:ARRY) announced the appointment of Nicholas A. Saccomano, Ph.D., as Chief Scientific Officer of Array BioPharma, whose employment with Array will commence on May 30, 2014. Array Biopharma Inc. (NASDAQ:ARRY) ended the last trading day at $4.10. Company weekly volatility is calculated as 5.20% and price to cash ratio as 4.32.Array Biopharma Inc. (NASDAQ:ARRY) showed a positive weekly performance of 1.99%.
Pomerantz LLP announces the filing of a class action lawsuit against CytRx Corporation (NASDAQ:CYTR) and certain of its officers. The class action, filed in United States District Court, Central District of California and docketed under 14-cv-02689, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of CytRX between November 22, 2013 and March 13, 2014, both dates inclusive (the “Class Period”). CytRx Corporation (NASDAQ:CYTR) weekly performance is 12.72%. On last trading day company shares ended up $3.81. Analysts mean target price for the company is $11.00. CytRx Corporation (NASDAQ:CYTR) distance from 50-day simple moving average (SMA50) is 10.87%.